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The cancer stem cell (CSC) model has been established as a cellular mechanism that contributes to pheno-
typic and functional heterogeneity in diverse cancer types. Recent observations, however, have highlighted
many complexities and challenges: the CSC phenotype can vary substantially between patients, tumors may
harbor multiple phenotypically or genetically distinct CSCs, metastatic CSCs can evolve from primary CSCs,
and tumor cells may undergo reversible phenotypic changes. Although the CSC concept will have clinical
relevance in specific cases, accumulating evidence suggests that it will be imperative to target all CSC
subsets within the tumor to prevent relapse.Introduction
Phenotypic and functional heterogeneity is a defining feature of
many leukemias and solid tumors. Several factors contribute to
this heterogeneity, including genetic mutations, epigenetic
changes, interactions with the microenvironment, and the
presence or absence of a cellular hierarchy. Different cellular
mechanisms have been postulated to account for intratumoral
heterogeneity. The acquisition of genetic (or epigenetic) alter-
ations underpins the clonal evolution theory (Nowell, 1976) in
which cells in the dominant clonal population(s) possess similar
tumorigenic potential. Conversely, the cancer stem cell (CSC)
model postulates a hierarchical organization of cells such that
only a small subset is responsible for sustaining tumorigenesis
and establishing the cellular heterogeneity inherent in the
primary tumor. Although CSCs exhibit the stem cell properties
of self-renewal and differentiation, they do not necessarily origi-
nate from the transformation of normal tissue stem cells
(Figure 1). This model has received wide attention because it
provides an explanation for resistance to both radiation and
chemotherapy and eventual tumor relapse. In addition, quies-
cent or slow cycling CSCs may survive therapeutic intervention
and result in recurrence. The first prospective identification of
a CSC was made by Dick and colleagues for AML (Bonnet and
Dick, 1997; Lapidot et al., 1994). CSCs were subsequently
demonstrated to occur in diverse solid tumors (reviewed
in Visvader and Lindeman, 2008). Although the existence of
CSCs has been well established for specific cancers, it is clear
that the CSC model does not account for functional heteroge-
neity in all tumors.
Over the last few years, emphasis in the CSC field has shifted
more toward the use of freshly isolated tumor specimens and
early-passage xenografts for transplantation studies rather
than the use of cultured tumor cells. Furthermore, there is in-
creased awareness that the nature of the xenotransplantation
assay is critical for evaluating the existence of CSCs (Quintana
et al., 2008). Here we review recent developments in this rapidly
moving field, including the variable phenotype of CSCs, the pres-
ence of multiple CSC pools within individual tumors, the ability ofCSCs to undergo genetic evolution, and the potential of non-
CSCs to switch to CSC-like cells (Figure 2). These observations
highlight the dynamic nature of CSCs and further indicate that
the clonal evolution and CSC models can act in concert. They
also somewhat dampen the original therapeutic promise of the
CSC model, as it seems that all CSC subsets within the tumor
will need to be defined and targeted in order to influence clinical
outcome. In the case of solid tumors, which exhibit extraordinary
genomic instability, it will probably be necessary to target both
CSCs and non-CSCs to achieve durable remission. Despite
these complexities, the recent derivation of a stem cell-like or
‘‘self-renewal’’ gene expression signature that is predictive of
patient outcome in human leukemia lends credence to the
CSC hypothesis and its clinical relevance (Eppert et al., 2011;
Gentles et al., 2010).
CSC Markers Are Not Universal for Any Cancer Type
CSCs must be defined functionally by well-validated assays
such as in vivo transplantation rather than on the basis of immu-
nophenotype alone. Nonetheless, a number of markers have
proven useful for the isolation of subsets enriched for CSCs in
multiple types of solid tumors, including CD133, CD44, EpCAM,
and ALDH activity. In the case of human leukemia, a combination
of CD34, CD38, and IL3Ra has enabled the prospective isolation
of leukemia stem cells. It should be noted that none of these
markers are exclusively expressed by CSCs. With the passage
of time, it has become increasingly evident that the CSC pheno-
type varies between individual patient tumors of the same
subtype, raising the question of whether the markedly different
clinical outcomes reflect differences in their CSC populations.
CD133 (prominin) is one example of a cell surface protein that
has been widely explored as a CSC marker. CD133 was initially
described as a CSC marker for glioblastoma multiforme (Singh
et al., 2004). Moreover, direct imaging of matched CSCs and
non-CSCs in the same in vivo microenvironment of primary glio-
blastoma tumors demonstrated that only the CD133+ subset had
the ability to maintain tumorigenesis and generate heterogeneity
(Lathia et al., 2011a). However, CD133 does not always markCell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. 717
Figure 1. Schemata of the Clonal Evolution
and Cancer Stem Cell Models
(A) The clonal evolution model is a nonhierarchical
model where mutations arising in tumor cells
confer a selective growth advantage. Depicted
here is a cell (red) that has acquired a series of
mutations and produced a dominant clone. Tumor
cells (red and orange) arising from this clone have
similar tumorigenic capacity. Other derivatives
(grey) may lack tumorigenicity due to stochastic
events. Tumor heterogeneity results from the
diversity of cells present within the tumor.
(B) The cancer stem cell model is predicated on
a hierarchical organization of cells, where a small
subset of cells has the ability to sustain tumori-
genesis and generate heterogeneity through
differentiation. In the example shown, a muta-
tion(s) in a progenitor cell (depicted as the brown
cell) has endowed the tumor cell with stem cell-like
properties. These cells have self-renewing capa-
bility and give rise to a range of tumor cells (de-
picted as gray and green cells), thereby
accounting for tumor heterogeneity.
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search for more robust markers of CSCs in glioblastoma and
other brain tumors has revealed SSEA-1/CD15/Lewis X and
a6-integrin. SSEA-1 (stage-specific embryonic antigen) was
identified as a CSC marker in both human glioblastoma and
syngeneic mouse models of medulloblastoma (Read et al.,
2009; Son et al., 2009; Ward et al., 2009). Despite a high propor-
tion of specimens lacking CD133+ cells, SSEA-1 enriched for
CSCs by 100-fold in almost every human glioblastoma tumor
evaluated (Son et al., 2009). In another approach, Rich and
colleagues examined the perivascular microenvironment in
which brain CSCs reside and identified a6-integrin as a CSC
marker that was required for maintenance of CSCs in vivo (Lathia
et al., 2010). Coexpression of CD133 and a6-integrin was
observed in some but not all tumors.
The limited overlap evident between the phenotypes of CSCs
isolated from the same tumor type may reflect the presence of
multiple CSC pools or technical variation arising from differ-
ing enzymatic digestion conditions, the use of cultured versus
freshly sorted cells, or extensively passaged versus early xeno-
graft tumors. Another confounding factor is that stringent assays
to prove self-renewing activity have not always been applied.
The genetic mutation profile may also influence the nature and
phenotype of CSCs, as suggested by studies on different genetic
mouse models of lung adenocarcinoma (Curtis et al., 2010),
whereas epigenetic changes in regulatory genes could impact
marker expression itself. In breast cancer, although CD44
and CD24 have been extensively used to isolate CSCs, they
should not be viewed as universal markers. CD44 and CD24
did not selectively enrich for CSCs in ER-negative and triple-
negative breast tumors as shown by the fact that CSCs were718 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.found in both the CD44+CD24 and
CD44+CD24+ fractions (Meyer et al.,
2010). Furthermore, the ALDHhi and
CD44hiCD24lo CSC-enriched subsets in
breast cancer bear little overlap within
the same tumor (Ginestier et al., 2007). A
similar story holds true for colorectalcancer in which the EpCAMhiCD44+ CSC subpopulation
shared minor overlap with CD133 (Dalerba et al., 2007), and for
pancreatic cancer, where overlap between the CD133+ and
CD44+CD24+ populations varied considerably between speci-
mens (Hermann et al., 2007). In ovarian cancers, strikingly little
concordance was found between CD133 and reported ovarian
CSC markers including CD117, CD44, and ALDH1 activity
(Curley et al., 2009;Stewart et al., 2011),mostprobably explained
by many groups relying on cultured cells as opposed to freshly
sorted tumors. Finally, in patientswith non-small cell lung cancer,
although CD133, CD44, and EpCAM proved ineffective for the
isolation of CSCs, CD166 emerged as a robust marker in more
than 50%of cases (Zhang et al., 2012). Nevertheless, a combina-
tion of markers can refine the CSC phenotype. For example,
CD44expression combinedwith high levels of the tyrosine kinase
receptor c-MET provided robust selection of pancreatic CSCs
(Li et al., 2011), and high ALDH activity together with CD133
expression resulted in significant enrichment such that 1 in 11
ovarian tumor cells exhibited CSC properties (Silva et al., 2011).
Highly Variable Frequency of CSCs between Tumors
The true frequency of CSCs in most human tumors has probably
been underestimated because of barriers imposed by xeno-
transplantation, species-specific differences in growth factors/
receptors, and the level of immune recognition. However,
CSCs and tumor-initiating cells in many solid tumors tend to
be relatively infrequent, even when measured under more per-
missive conditions (Ishizawa et al., 2010; Stewart et al., 2011).
The term ‘‘tumor-initiating’’ is generally used by the field as an
operational term to define cells that initiate tumors upon trans-
plantation but it is not necessarily synonymous with a CSC.
Figure 2. Schematic Models of Tumor Propagation by CSCs
Depicting Variations that Can Contribute to Tumor Heterogeneity
(A) One CSC subset may be present within the tumor. As described in Figure 1,
non-CSCs are incapable of generating a tumor.
(B) Multiple distinct CSC pools, each independently capable of tumor propa-
gation, may exist with an individual tumor.
(C) Long-lived dormant CSCs may produce local and/or distant tumor recur-
rence after activation (depicted here as a yellow CSC with a red rim) many
years after anticancer therapy.
(D) As tumor progression occurs, a second distinct CSC may arise as a result
of clonal evolution. This may result from the acquisition of an additional
mutation or by epigeneticmodification. Themore aggressive CSCwill become
dominant and drive tumor formation.
(E) The CSC phenotype may be unstable, resulting in phenotypic reversion of
cell surface markers and switching of the CSC phenotype. This may occur in
response to cell-intrinsic or microenvironmental cues.
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initiating cells but these do not exhibit stem cell-like properties.
In head and neck, pancreatic, and non-small cell lung cancers,
the frequency of tumor-initiating cells varied dramatically but
always comprised a very small population (<0.02%). Interest-
ingly, the frequency was not dependent on the immune status
of the recipient (Ishizawa et al., 2010). CSCs in serous ovarian
cancers were also found to be infrequent (<0.04%) and again
varied substantially among patients (Stewart et al., 2011). Anal-
ogous to these observations, evaluation of leukemic stem cells
(LSCs) under improved xenotransplantation conditions revealed
highly variable LSC frequencies in the range of 1 in 103106 cells
(Eppert et al., 2011).
CSCs may not necessarily constitute a minor component of
the tumor. A relatively high proportion of leukemia-propagating
cells has been observed in specific syngeneic mouse models
of lymphomas and leukemias, whereas lower frequencies of
CSCs generally occur in murine models of epithelial and other
solid tumors (reviewed in Visvader and Lindeman, 2008). Inter-estingly, initiating ‘‘driver’’ mutations were found to affect the
frequencies of LSCs in mouse models of AML (Heuser et al.,
2009; Somervaille et al., 2009). In high-grade tumors from
patients, an increased pool of CSCs may underlie their aggres-
sive behavior (Boiko et al., 2010; Pece et al., 2010; Zhang
et al., 2012). Indeed, the CSC model of heterogeneity may apply
more readily to early-stage than to advanced tumors, in which
dominant clones probably drive tumor progression.
Instability of the CSC Phenotype
Substantial differences in the immunophenotype of tumor-
propagating cells between primary cancer specimens and their
corresponding xenografts have been reported. Whereas most
primary serous ovarian cancers contained CD133+ CSCs, the
majority of xenografted tumors contained significant numbers
of CD133 tumor-initiating cells that could not be attributed to
contamination (Stewart et al., 2011). The marked changes in
copy number variation between these primary and xenografted
tumors suggest that genetic change is driving tumor progres-
sion, although the pre-existence of subclonal diversity cannot
be excluded. These data not only reflect heterogeneity within
the tumor-propagating compartment but also indicate that the
CSC phenotype may not be stable upon xenograft passaging.
Although the frequency of CSCs for some ovarian (Stewart
et al., 2011) and breast cancer (Meyer et al., 2010) xenografts
remained constant, the frequency of CSCs has been observed
to increase during serial transplantation, thus emphasizing the
need to study early-passage tumors (Boiko et al., 2010; Ishizawa
et al., 2010).
Existence of Multiple CSC Pools within Individual
Tumors
Cancers can harbor heterogeneous and biologically distinct
populations of CSCs. Recent studies have identified molecularly
distinct leukemic stem cell populations defined by CD34, CD38,
and/or IL3Ra expression. In the majority of AML patients, two
hierarchically organized LSCs were shown to coexist. These
populations are more closely related to normal progenitor
subtypes than hematopoietic stem cells (HSCs) (Goardon
et al., 2011), implying that the progenitors have aberrantly
acquired stem cell properties. Complementary findings were
made with a large number of AML patient samples, in which
both progenitor and more primitive HSC-like fractions contained
LSCs and generated the same phenotypic diversity found in the
primary samples (Eppert et al., 2011; Sarry et al., 2011). Notably,
another study revealed that CD38+ AML cells may have previ-
ously escaped detection because of their unexpected clearance
by the antibody (Taussig et al., 2008). In a HoxA9-Meis1-driven
mouse model of AML, multiple phenotypically distinct LSCs
were identified, and each was capable of recapitulating the orig-
inal disease histopathology (Gibbs et al., 2012). Collectively,
these findings demonstrate heterogeneity within the LSC com-
partment of individual patient specimens and also indicate that
AML often appears as a progenitor disease. In at least some of
these AMLs, a hierarchical relationship appears to exist among
the different LSC subsets. The observation that different pools
can clonally recapitulate the immunophenotype of the primary
specimen suggests that LSCs may dedifferentiate or exhibit
phenotypic interconversion.Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. 719
Figure 3. CSC Subsets within Primary Tumors May Harbor
Metastatic and Tumor-Propagating Capacity
(A) A CSC may be responsible for both local and disseminated tumor propa-
gation. In the example shown, a CSC (blue) enters the vasculature and
metastasizes to a distant organ, where it seeds a heterogeneous tumor
deposit exhibiting the hallmark features of the primary tumor.
(B) Alternatively, genetic and/or epigenetic mechanisms acting in the primary
CSC could lead to the emergence of a self-renewing metastatic CSC (green)
expressing distinct markers from the original CSC. This metastatic CSC,
through a series of invasive processes, seeds secondary tumors in distant
organs.
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unmasked in solid tumors. In ovarian, breast, and squamous
cell carcinomas, distinct CSC populations that regenerate the
phenotypic and functional heterogeneity of the parental tumor
have been described (Meyer et al., 2010; Schober and Fuchs,
2011; Stewart et al., 2011). In the case of primary colorectal
cancers, three different types of tumor-initiating cells were
resolved on the basis of clonal sphere cultures from individual
patient tumors: a rare subset of CSCs that maintained tumor
growth on serial transplantation, a tumor-initiating cell with
limited self-renewal capacity (therefore not defined as a CSC),
and a more latent CSC that apparently was activated in sec-
ondary or tertiary transplantation assays (Dieter et al., 2011).
Because spheres generated from single cells comprised three
cell types defined by differences in self-renewal, epigenetic
rather than genetic mechanisms may account for the functional
differences. Clonal heterogeneity among tumor-initiating cells
was also observed in PTEN-deficient glioblastoma, in which a
series of phenotypically distinct self-renewing cells was ob-
served in both the CD133+ and CD133 fractions (Chen et al.,
2010). These cells were arranged in a linear hierarchy and gener-
ated tumors with different growth kinetics in serial transplanta-
tion experiments. However, both of these studies relied on
sphere cultures of cells maintained under specific conditions,
and therefore need to be validatedwith fresh primary tumor sam-
ples. Although tumor-propagating ability can reflect sphere-
forming capacity, it is important to note that they do not always
equate because the selection of specific cells may occur in vitro
(Read et al., 2009).
Adding a further layer of complexity, distinct CSC subsets
within a tumor have the potential to interconvert. In skin squa-
mous cell carcinomas, two CSC subsets located along the
tumor-stroma interface displayed different tumor growth kinetics
and could interchange phenotype (Schober and Fuchs, 2011).
These may not represent distinct CSC pools but rather sto-
chastic variation within a single CSC population in response to
microenvironmental signals. Phenotypic conversion also occurs
among nonhierarchically organized tumor cells in melanoma
(Quintana et al., 2010).
Metastatic CSCs May Be the Same or Distinct from
the Primary CSC
There is growing evidence for the existence of functionally
distinct subsets of tumor cells that impart metastatic activity.
CSC subsets within primary tumors may harbor CSC subsets
with tumor-propagating and/or metastatic capacity (Figure 3).
In breast cancer, noninvasive imaging indicated that primary
tumor CSCs characterized by CD44 expression are directly
involved in metastasis (Liu et al., 2010). Similarly, in colorectal
cancer, metastasis was almost exclusively a property of the
CSCs that exhibited long-term self-renewing capacity (Dieter
et al., 2011). Multiple disseminating CSCs homed to the bone
marrow and generated liver metastases but only single clones
were detected in peripheral blood, suggesting that metastatic
CSCs enter the circulation transiently. In a related study on colo-
rectal cancer, a subset of CD26+ cells resident within primary
and metastatic tumors demonstrated tumor propagation, che-
moresistance, and liver metastatic potential after implantation
at the orthotopic site (the cecal wall). Significantly, the presence720 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.of CD26+ cells in primary tumors also predicted metastasis in
patients (Pang et al., 2010). In these epithelial malignancies,
the epithelial mesenchymal transition (EMT) may underlie the
metastatic process and give rise to precursors of metastatic
CSCs at the invading edge of the tumor (Mani et al., 2008).
In other tumors, a unique subset of metastatic CSCsmay drive
metastasis. In pancreatic cancer, only CD133+CXCR4+ cells
(not CD133+CXCR4 cells) demonstrated metastatic activity,
despite both subsets having tumor-propagating capacity
(Hermann et al., 2007). Moreover, inhibition of CXCR4 signaling
profoundly reduced the metastatic potential of pancreatic
tumors without altering their tumorigenic potential. This meta-
static CSC may have evolved from the primary tumor CSC or,
alternatively, from a non-CSC within the tumor. The delineation
of functionally distinct pools of CSCs will ultimately require cell
tracing studies in vivo, via either mouse models relevant to
human disease or minimally manipulated human cells for trans-
plantation. Tracking of tumor cells in the circulation should also
provide insight into metastatic CSCs.
Not All Cancers Harbor CSCs
Not all cancers will be sustained by CSCs. In melanoma, the high
proportion of tumorigenic cells (as many as 50%) assayed
Cell Stem Cell
Perspectiveunder more permissive conditions and with a wide spectrum of
markers (e.g., CD271), argues against a CSCmodel of heteroge-
neity (Quintana et al., 2010). On the other hand, there are data
from two groups indicating that melanoma lesions contain
a CSC subset characterized by CD271 expression with nude
recipient mice (Boiko et al., 2010; Civenni et al., 2011). However,
in more immunocompromised strains such as NOD-SCID-
IL2Rg/– mice, both subsets were found to be tumorigenic,
although the CD271 fraction did not phenocopy the original
tumor histology (Civenni et al., 2011). One factor contributing
to these disparities (besides recipient strain) will include the
use of trypsin during tissue dissociation (Quintana et al., 2010),
given that the CD271 antigen was shown to be sensitive to this
enzyme (Civenni et al., 2011). Thus, the inclusion of trypsin in
the dissociation procedure will result in contamination of the
negative fraction with cells that actually express the antigen.
Nevertheless, a large number of markers evaluated by Morrison
and colleagues (Quintana et al., 2010) yielded cell populations
that were tumorigenic irrespective of marker expression. It
seems plausible that other parameters such as implantation
conditions and tumor grade also contribute to the discrepant
findings. Another potential issue is that the frequency of CSCs
can vary widely from 2.5% to 41% (Boiko et al., 2010), suggest-
ing that the CSC model is not applicable to those tumors con-
taining a high proportion of tumor-forming cells. Melanoma
may also use distinct cellular mechanisms from most other solid
malignancies, given the highly migratory nature of neural crest
cells and their ability to respond to immune-based therapies.
Role of the CSC Niche
Cancers comprise malignant cells together with inflammatory
cells, hematopoietic cells, associated stroma, and vasculature.
Although some CSCs conceivably do not require a dedicated
niche, others will be dependent on a specific set of extrinsic
interactions with their microenvironment. The niche effect on
tumor cells may be inductive or selective but will inevitably differ
for every tumor subtype. The perivascular niche of CSCs in brain
cancers is the best characterized to date (reviewed in Gilbertson
and Rich, 2007). In at least some glioblastomas, the relationship
between the CSC and local environment appears to be bidirec-
tional: the niche can alter the cellular fate of cancer cells and,
conversely, CSCs can modify their microenvironment (Heddles-
ton et al., 2009; Hjelmeland et al., 2011; Ricci-Vitiani et al., 2010;
Wang et al., 2010b). Indeed, CSCs in glioblastoma have been
demonstrated to secrete VEGF that directly supports the devel-
opment of the local vasculature (Gilbertson and Rich, 2007). In
the reverse direction, endothelial cells secrete nitric oxide that
induces Notch signaling in glioma cells (Charles et al., 2010). It
is relevant that CSCs but not non-CSCs in gliomas were shown
to be dependent on nitric oxide synthase-2 (Eyler et al., 2011).
Intriguingly, CSCs in glioblastomas can directly contribute to
the microvasculature through their transdifferentiation into
vascular cells (Ricci-Vitiani et al., 2010; Wang et al., 2010b),
underscoring the close relationship between brain CSCs and
their niche. The perivascular niche also serves a crucial role in
the case of cutaneous squamous cell carcinomas. CSCs in this
vascular niche establish an autocrine loop in which VEGF
promotes CSC activity by governing both the microenvironment
and intrinsic self-renewal pathways in CSCs (Beck et al., 2011).Even in nonsolid tumors, microenvironmental cues from cyto-
kines, growth factors, or the immune-deficient strain play an
instructive role in determining the lineage fate of LSCs in a human
model of leukemia (Wei et al., 2008). Hence, there has been
considerable interest in targeting the putative CSC niche.
Cells within the tumor-associated stroma, such as myofibro-
blasts, are likely to have a prominent role in controlling CSC
homeostasis in many tumor types. In colorectal cancer, myofi-
broblasts secrete HGF that maintains CSC function by activating
the Wnt pathway. Interestingly, tumor cells with an active Wnt
canonical pathway were preferentially located adjacent to
stromal myofibroblasts (Vermeulen et al., 2010). Moreover,
HGF-mediated activation of the Wnt pathway could induce
CSC features and tumorigenic capacity in differentiated cancer
cells that otherwise had limited tumorigenic capacity. Although
these studies used spheroid cultures of primary colorectal
cancers rather than fresh patient specimens, they suggest that
the microenvironment can govern tumor cell ‘‘stemness.’’ Selec-
tive targeting of myofibroblasts or the HGF/c-MET pathway
would be predicted to interfere with the maintenance of CSCs
and to potentially prevent the generation of CSCs from the
non-CSC compartment. Notably, HGF is a potent inducer of
the EMT,which plays a role inmediating invasion andmetastasis.
Using a mouse model of mammary tumorigenesis, another
stromal factor, periostin, was shown to be essential for meta-
static colonization by governing interactions between CSCs
and their metastatic niche (Malanchi et al., 2012). Finally, the
perturbation of other stromal mesenchymal cells such as osteo-
progenitors candisrupt homeostasis, resulting inmyelodysplasia
and secondary leukemia (Raaijmakers et al., 2010). These find-
ings support the notion of niche-induced transformation and
suggest that selective targeting of the tumor microenvironment
may represent an alternative or adjunct to targeting the CSC.
Even though it will be extraordinarily difficult to delineate the
niche for human tumor CSCs and recapitulate the immune
system of cancer patients, it is crucial to use an orthotopic trans-
plantation assay to mimic the tumor environment as closely as
possible. The coinoculation of human stromal cells to create
a more appropriate environment for tumor development is also
a relevant parameter to consider. The site of injection has been
shown to directly influence the frequency of tumor-initiating
cells, underscoring the relevance of context. For example, the
frequency of tumor-initiating cells in ovarian tumors was highest
and most reliably read-out by the mammary fat pad assay rather
than the ovarian bursa (Stewart et al., 2011). However, the ques-
tions arise as to why thesemicroenvironments differentially influ-
ence cell tumorigenicity and whether the tumor-initiating cells
measured in the fat pad are in fact different from those assayed
in the ovarian bursa.
Pathways Regulating CSC Function
Elucidation of the pathways that regulate the maintenance and
survival of CSCs is important for the development of novel ther-
apies. Not surprisingly, many CSC subsets and normal tissue
stem cells seem to share core regulatory genes and develop-
mental pathways such as c-myc, Bmi-1, and the Hedgehog
(Hh), Notch, and Wnt pathways. Indeed, there is substantial
evidence that restricted progenitors can generate LSCs by the
reactivation of distinct self-renewal programs (Krivtsov et al.,Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. 721
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chronic myeloid leukemia (CML), Hh signaling is essential for the
maintenance and function of LSCs, and loss of Hh activity via
disruption of Smoothened led to depletion of LSCs in vivo and
prolonged animal survival (Dierks et al., 2008; Zhao et al.,
2009). In the transition to the blast cell crisis phase, the LSC
appears to originate from the granulocyte-macrophage progen-
itor cell through the acquired activation of the Wnt pathway
(Jamieson et al., 2004). The Wnt pathway also plays a prominent
role in the generation and self-renewal of LSCs in AML (Wang
et al., 2010c). Significantly, b-catenin activation endowed pro-
genitor cells with self-renewing capability but was not essential
for the renewal of normal adult HSCs. Parallel findings were
made for cutaneous CSCs versus normal skin stem cells in
mouse models of skin cancer (Malanchi et al., 2008). Hence,
the genetic programs governing self-renewal may be differen-
tially active in normal and malignant stem cells, thereby opening
therapeutic avenues.
Cell polarity andmetabolic pathways have recently been impli-
cated in governing the function of CSCs. TAZ, a transcriptional
effector in the Hippo pathway, was found to be frequently over-
expressed in high-grade breast cancers and to maintain the self-
renewing capacity of tumorigenic cells isolated from established
cell lines (Cordenonsi et al., 2011). A key link was established
between the Hippo pathway and the cell polarity gene Scribbled,
suggesting that cell polarity pathwaysmay impact CSC function.
It will be important to extend these studies to fresh tumor spec-
imens because cancer cell lines do not reflect in vivo tumor cell
behavior. In a metabolic context, glycine decarboxylase was
demonstrated to regulate the activity of tumor-propagating cells
in non-small cell lung cancer (Zhang et al., 2012). Aberrant
expression of glycine decarboxylase occurs in multiple cancer
types and leads to changes in glycine/serine metabolism. The
observation that CSC activity was dependent on glycine decar-
boxylase function provides a direct link between glycine metab-
olism and tumorigenesis. Although it is presumed that metabolic
processes play a crucial role in all tumor cells, it is intriguing that
they can selectively influence CSC function.
CSCs and Stemness Signatures
In spite of the heterogeneity exhibited by CSCs, recent gene
expression profiling studies have provided important insights
into the prognostic significance of CSCs. The molecular anal-
yses of functionally defined LSC populations from AML patients
led to the generation of a LSC signature that largely reflects
a self-renewal or stemness signature (Eppert et al., 2011). This
signature was found to be a strong predictor of poor prognosis,
with the implication that it may be possible to identify patients at
highest risk and to inform both the type and duration of their
therapy. In a murine model of AML, a conserved signal transduc-
tion network was unveiled among different LSCs (Gibbs et al.,
2012). Other recently derived ‘‘stem cell’’ signatures also exhibit
prognostic value. In colorectal cancer, a gene signature derived
for adult intestinal stem cells predicted relapse in patients
and identified EphB2-positive CSCs in tumors (Merlos-Sua´rez
et al., 2011). Moreover, an embryonic stem cell (ESC)- andmeta-
static cell-based stem cell signature was found to increase with
tumor grade and mortality in multiple tumor types (Shats et al.,
2011), while an ESC-like transcriptional program evident in722 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.diverse epithelial cancers predicted poor prognosis (Wong
et al., 2008). Preliminary data suggest that activation of this tran-
scriptional program in adult cells may lead to the generation of
CSCs. Another important player in ESCs, STAT3, was implicated
in maintaining the stemness of glioma CSCs (Guryanova et al.,
2011). Overall, these findings suggest that targeting self-renewal
pathways may represent one of the most effective strategies for
eradicating CSCs (see below).
Therapeutic Strategies to Target CSCs
From a clinical perspective, it is important to decipher mecha-
nisms of chemo- and radioresistance that operate in CSCs.
Quiescent CSCs are thought to be more resistant to therapies
while most CSCs seem to evade cytotoxic or radiotherapy
through active mechanisms. There is clinical evidence for a
subpopulation of chemotherapy-resistant ‘‘CSCs’’ in a number
of solid tumors including breast cancer (Li et al., 2008; Yu
et al., 2007). Furthermore, the analysis of breast tissue taken
from patients pre- and postendocrine therapy or chemotherapy
for gene expression changes revealed that residual breast
cancers may be enriched for tumor cells with CSC-like and
mesenchymal characteristics (Creighton et al., 2009). In patients
with del(5q) myelodysplastic syndrome, rare stem cells were
found to be refractory to therapeutic targeting in individuals in
remission, which probably accounts for relapse (Tehranchi
et al., 2010).
Different aspects of CSCs have been explored in recent
targeting strategies including quiescence, self-renewal path-
ways, radioresistance, and CSC-specific cell surface molecules.
Several reports, predominantly for hematopoietic malignancies,
indicate that CSCs can be selectively targeted without ablating
normal stem cell function. Stem cell maintenance pathways
are emerging as prime targets to eradicate CSCs. This ap-
proach, however, will be applicable only if the genetic programs
controlling self-renewal are differentially active in malignant
versus normal stem cells. It will be imperative to carefully eval-
uate the toxicity of anti-CSC agents on normal stem cell function
in preclinical models. There are little data on the use of differen-
tiation therapy in the context of CSCs but BMPsmay be effective
in inducing glial differentiation in glioblastomas and attenuating
tumor growth (Piccirillo et al., 2006). In all likelihood, given the
large number of mutations incurred by solid tumors such as
breast (Wood et al., 2007), it will be essential to target multiple
pathways that have been activated in CSCs in a given tumor.
Quiescence or dormancy is a property of at least some CSCs
such as those in leukemia. This feature has recently been ex-
ploited to provide a window for therapeutic intervention. Cyto-
kines such as G-CSF efficiently induced quiescent LSCs in
AML to enter the cell cycle, thus sensitizing them to different
chemotherapeutic agents (Saito et al., 2010). Indeed, combined
G-CSF with chemotherapy elicited profound apoptosis and
eradication of human AML stem cells in vivo. Inhibition of DNA
repair mechanisms may also be harnessed for eradication of
slow cycling LSCs (Viale et al., 2009). Although LSCs may reside
in amore quiescent state, emerging evidence suggests that solid
tumor CSCs follow a different pattern. In glioblastoma, CSCs are
actively self-renewing and cellular diversity is most probably
generated through symmetric cell division (Lathia et al., 2011b).
Despite the observation that mouse mammary CSCs appear to
Figure 4. Possible Mechanisms of Metastatic Relapse after Anticancer Therapy and Evaluation of Anti-CSC Treatments
(A) Late relapse can be accounted for by CSC dormancy. Here a dormant CSC (pink) that is resistant to both chemotherapy and targeted therapy has seeded to
distant organs. After a considerable latency period, reactivation of a CSCwill result in tumor growth and clinical emergence ofmetastases. Intriguingly, the clinical
appearance of metastases is often synchronous in breast cancer.
(B) One of the challenges facing the field is the clinical translation of anti-CSC therapies. Strategies will need to be deployed in clinical trials that enable
reproducible assays of CSC activity. In the scenario depicted here, biopsy material from a newly diagnosed breast cancer is subjected to a variety of assays to
measure CSCs, including functional assays and gene expression profiling, in parallel with the collection of blood samples and tumor imaging. The latter could
include nanoparticle-labeling of anti-CSC markers coupled with in vivo imaging. These assays can be repeated after neoadjuvant therapy to determine whether
the therapy has elicited a response against putative CSCs.
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mary stem cells in mammosphere cultures (Cicalese et al.,
2009), it is tempting to speculate that the long period between
primary tumor detection and relapse in patients with ER-positive
breast cancer (up to 20 years) may reflect a dormant stem cell
subset (Figure 4).
Of the key developmental pathways frequently deregulated in
CSCs, considerable progress has been made in the case of
targeted therapies against Notch and Hh, but the development
of Wnt inhibitors has proven difficult. Significantly, pharmaco-
logic inhibition of the Hh pathway in human and mouse leuke-
mias inhibited the expansion of imatinib-resistant CML (Dierks
et al., 2008; Zhao et al., 2009). These findings have profound
implications because they suggest that treatment of imatinib-
resistant recurrence in CML patients may be achievable via
targeting the Hh pathway. However, because Hh pathway
activity is required for maintenance of normal HSCs, it will be
crucial to determine the effects of these anticancer agents on
all aspects of normal HSC function. Pharmacologic or siRNA-mediated inhibition of Hh signaling in CSCs in glioblastoma,
medulloblastoma, breast, pancreatic adenocarcinoma, andmul-
tiple myeloma has resulted in markedly reduced tumorigenic
potential and, in some cases, ameliorated metastasis (reviewed
inMerchant andMatsui, 2010). Hh ligandsmay play a dual role in
the maintenance of CSCs and their niche, given the high stromal
expression of these ligands. In terms of Notch signaling, CSCs in
brain cancer were rendered more sensitive to radiation by
blockade of this pathway (Wang et al., 2010a). Notably, Notch
pathway inhibition via a neutralizing antibody against the DLL4
ligand was effective in reducing CSC numbers in diverse solid
tumor xenografts (Hoey et al., 2009), whereas inhibition of
Notch-4 expressed within the CSC subset largely ablated breast
tumor growth (Harrison et al., 2010). A combination of Notch and
Hh signaling may drive the self-renewal of CSCs in certain
tumors such as undifferentiated pleomorphic sarcomas (Wang
et al., 2012). Other self-renewal programs such as those regu-
lated by Nodal and Activin, factors important for ESC mainte-
nance, are also candidate targets. Pharmacologic inhibition ofCell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. 723
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a human xenograft model and significantly prolonged survival
when combined with a stroma-targeting Hh inhibitor to improve
drug delivery (Lonardo et al., 2011).
There has been considerable interest in the development of
monoclonal antibodies to target CSCs. Markers differentially
expressed between normal stem cells and LSCs have been
utilized to specifically target LSCs in human AML, including
CD44 (Jin et al., 2006), IL3R (Jin et al., 2009), and the immuno-
globulin mucin TIM-3 (Kikushige et al., 2010). In each case, treat-
ment with antibodies against these cell surface molecules
dramatically decreased leukemogenicity and eradicated LSCs
as assessed by AML reconstitution inmice. Furthermore, the tar-
geting of CD44 provides a paradigm for targeting CSC-niche
interactions. Blocking antibodies against CD47, which serves
as a ‘‘don’t eat me’’ signal to tumor macrophages, may also be
effective in eliminating LSCs in ALL that express higher levels
of this antigen than their normal counterpart (Chao et al., 2011).
Several studies have highlighted the radioresistance of CSCs
in solid tumors, particularly in brain cancer. CSCs in fresh glio-
blastoma specimens or glioma xenografts are more resistant
to ionizing irradiation (IR) in vivo than non-CSCs because of
enhanced DNA repair pathways operating in CSCs (reviewed
in Gilbertson and Rich, 2007). In medulloblastoma, targeting of
cells in the perivascular region with Akt inhibitors enhanced
responsiveness to radiation (Hambardzumyan et al., 2008), indi-
cating that the CSC niche itself may serve as a therapeutic
target. Interestingly, the DNA damage checkpoint response
and radioresistance of CSCs in glioma is regulated in part by
the adhesion molecule L1CAM through the activation of the
ATM kinase pathway (Cheng et al., 2011). Similarly, radioresist-
ance has been implicated in breast CSC-like populations that
are thought to repair DNA damage more efficiently. Inhibition
of the Akt pathway led to the selective targeting of CSCs by
blocking canonical WNT signaling and repair of DNA damage
in these cells, thus sensitizing them to ionizing radiation (Zhang
et al., 2010). In some breast tumors, lower ROS levels were found
in certain CSC subsets compared with their nontumorigenic
counterparts, perhaps conferring resistance to ionizing radiation
(Diehn et al., 2009).
Other therapeutic targets currently being pursued in the
context of CSCs include growth factor receptor signaling
networks. In pancreatic cancer, inhibition of the c-MET tyrosine
kinase receptor diminished the CSC population and prevented
metastasis, either alone or in combination with gemcitabine
(Li et al., 2011). These inhibitors may also prove efficacious in
colorectal cancer (Vermeulen et al., 2010). Recent studies on
squamous carcinoma revealed that selective inhibition of VEGF
signaling reduced CSC activity and led to tumor regression
(Beck et al., 2011), implying that it may be necessary to target
both CSCs and the stroma in which they reside. Cytokine path-
ways such as IL-8/CXCR1 are also emerging as important
modulators of CSC activity. Repertaxin-mediated inhibition of
this pathway reduced breast tumorigenesis and metastasis but
only in combination with chemotherapy (Ginestier et al., 2010).
In the search for novel drug discovery platforms, high
throughput screens using small molecule, miRNA, or siRNA
libraries have become an area of increasing focus. The applica-
tion of a high throughput screen to target breast CSCs revealed724 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.a class of compounds that had previously not been implicated as
cancer drugs: salinomycin-reduced tumor growth and lung
metastases, possibly via direct targeting of breast CSCs
(Gupta et al., 2009). An analogous screen to identify small
molecule inhibitors of LSCs in AML led to the recent discovery
of kinetic riboside (McDermott et al., 2012). MicroRNA-based
therapies are emerging as novel modes of therapeutic
intervention. Notably, systemic delivery of miR-34a, which is
expressed at low levels in prostate CSCs, inhibited metastasis
of prostate cancer cells and prolonged survival of mice (Liu
et al., 2011). It is relevant that miR-34a targets CD44, a cell
surface marker used to enrich prostate CSCs. Further large-
scale screens should be enabled by the development of
improved surrogate in vitro culture assays that maintain the
integrity of primary tumor-derived CSCs, rather than the use of
cell lines. Ultimately, the testing of all putative anti-CSC agents
requires preclinical mouse models containing early passage
xenografts (or leukemic cells) to obviate any changes that occur
upon prolonged passage.
Evolution of CSCs and Tumor Cell ‘‘Plasticity’’
It is important to note that the CSC and clonal evolution concepts
are not mutually exclusive. Two recent papers have highlighted
a high degree of convergence between these models in
leukemia. LSCs in acute lymphoblastic leukemia harboring the
ETV6-Runx1 translocation were shown to be genetically diverse,
exhibiting different degrees of self-renewing and leukemogenic
activity in vivo (Anderson et al., 2011). This study provides
evidence that CSCs within individual cancer patients can be
genetically heterogeneous, presumably accounting for their
variable biological properties such as self-renewal potential.
Moreover, in BCR-ABL acute lymphoblastic leukemia patients,
the leukemia-initiating population displayed profound genetic
diversity, with multiple genetically distinct tumor-initiating sub-
clones at diagnosis (Notta et al., 2011). Although it has not yet
been determined whether these tumor-initiating cells follow the
CSC model, it seems likely. In parallel with the other study,
a nonlinear, branching model of tumor evolution was identified.
Taken together, these studies illustrate the importance of com-
plementing functional assays of cellular heterogeneity with
genetic fingerprinting of the different subsets.
In addition to genetic variegation, tumor cell plasticity may
contribute to phenotypic and functional heterogeneity. Many
cell surface markers on melanoma cells are reversibly ex-
pressed, such that phenotypically diverse melanoma cells can
recapitulate tumor heterogeneity of the parent tumor, irrespec-
tive of whether they arose from marker-positive or marker-
negative cells (Quintana et al., 2010). Regulatory genes may
also be transiently or stochastically expressed. JARID1B-
mediated histone demethylationwas demonstrated to be revers-
ibly expressed in melanoma cell lines and to be essential for the
maintenance of tumorigenic activity (Roesch et al., 2010). Slow
cycling JARID1B-expressing cells could arise from a negative
population even when initiated from a single cell, suggesting
that a nontumorigenic cell may reacquire stem cell-like proper-
ties. In addition, cells within breast cancer cell lines were found
to transition stochastically between states to establish a stable
phenotypic equilibrium (Gupta et al., 2011), and CSC-like cells
could arise de novo from transformed breast epithelial cells
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version might occur in a stochastic manner.
CSC function may be induced by specific microenvironmental
cues from growth factors or in stress-related contexts. For
example, HGF has been implicated in the reprogramming of
non-CSCs toward a CSC-like phenotype in colon cancer (Ver-
meulen et al., 2010). Furthermore, induction of an EMT in immor-
talized human breast epithelial cells can endow them with stem
cell-like properties and potentially promote the generation of
CSCs from tumor cells (Mani et al., 2008). HIF2a, induced as
a cellular response to a hypoxic microenvironment, has been
implicated in the maintenance of CSCs in glioblastoma and
may promote the interconversion of nonstem (CD133) to
CSC-like cells (Heddleston et al., 2009; Li et al., 2009). The re-
versible state, in its various guises discussed above, has pro-
found implications for the treatment and management of
patients. Moreover, therapeutic resistance itself may potentially
reflect a reversible state (Sharma et al., 2010).
Finally, it should be noted that many of the studies described in
this section used cell lines or cultured primary cells, and that at
present there is no evidence for dedifferentiation occurring in
primary tumors in vivo. However, it is noteworthy that dedifferen-
tiation can occur at a low frequency in normal tissues such as the
testis (Barroca et al., 2009). Because definitive cell surface
markers are lacking for most stem cells and their descendants,
at least in solid organs, it is difficult to study cellular plasticity.
Further elucidation of differentiation hierarchies may eventually
enable ‘‘plasticity’’ and interconversion of cells between nontu-
morigenic and tumorigenic states to be formally tested by clonal
cell tracking analysis in vivo.
Conclusions
An emerging consensus in the field is that ‘‘cellular state’’ rather
than phenotype is important when defining a CSC. The unifor-
mity between LSC signatures that has emerged across diverse
samples, despite interpatient variation in CSCmarkers, confirms
that current phenotypic markers are not a reliable measure of
CSCs. One corollary of high interpatient variation is that an
extensive range of markers will need to be validated in a large
number of patient samples, perhaps even necessitating func-
tional assessment for each patient. Indeed, the purification of
CSCs using a robust set of markers, even from a given tumor
subtype, remains a major challenge for the field. If CSCs exist
in a dynamic state in certain tumors, then this will inevitably
confound their prospective isolation. The existence of multiple
CSC pools or evolving intratumoral clones in individual tumors
demands the monitoring of these populations in pre- and
posttreatment samples by multicolor flow cytometry or high-
resolution molecular imaging to identify residual cells that might
drive relapse (Figure 4). The derivation of robust signatures that
distinguish CSCs from normal stem cells may also facilitate the
evaluation of clinically relevant residual cells.
The clinical applicability of the CSC concept to predicting
patient response remains a fundamental question. Most putative
anti-CSC therapies to date have attenuated rather than eradi-
cated solid tumors in preclinical models, and efficacious
response often required concomitant chemotherapy. In order
to improve the evaluation of efficacy of anti-CSC agents in clin-
ical trials, there is a pressing need to optimize assays for CSCtargeting and measurement of tumor response. In standard
clinical trials, tumor response criteria depend on measurements
of tumor size, which largely reflects tumor response in the non-
CSC tumor bulk. Specific response criteria that provide a read-
out of response to anti-CSC agents in clinical trials remain
elusive (Figure 4). Tumor sphere-forming assays and measure-
ment of CSC marker expression are unlikely to provide robust
surrogate markers in a clinical setting. The incorporation of other
measures such as self-renewal activity into therapeutic strate-
gies will almost certainly be required. We speculate that for
most tumor types it will still prove necessary to test novel anti-
CSC therapies in combination with tumor debulking (non-CSC)
therapy, such as conventional chemotherapy.
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